Overview

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.

Phase:

Phase 2

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Carboplatin
Cisplatin
Pemetrexed